Annotation Detail

Information
Associated Genes
FGF3
Associated Variants
FGF3 AMPLIFICATION ( ENST00000334134.4 )
FGF3 AMPLIFICATION ( ENST00000334134.4 )
Associated Disease
breast cancer
Source Database
CIViC Evidence
Description
81 patients were enrolled in a clinical trial with the FGFR inhibitor dovitinib. Four of these patients had FGF3 amplifications (qPCR) and showed tumor reductions of 100%, 30.8%, 23.0%, and 7.5%, respectively. 3 of these 4 patients also had FGFR1 amplifications (≥6 copies by qPCR) and the fourth presented with FGFR1-gene gain (3.4 copies of FGFR1 by qPCR and SISH negative).
Variant Origin
N/A
Variant Origin
N/A
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1606
Gene URL
https://civic.genome.wustl.edu/links/genes/1873
Variant URL
https://civic.genome.wustl.edu/links/variants/630
Rating
2
Evidence Type
Predictive
Disease
Breast Cancer
Evidence Direction
Supports
Drug
Dovitinib
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
23658459
Drugs
Drug NameSensitivitySupported
DovitinibSensitivitytrue